Clinical Trial

A Study of Efficacy and Safety of TLL-018 in CSU Participants

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TLL-018 in Participants With Moderate-to-Severe Chronic Spontaneous Urticaria (CSU) With Inadequate Controll to Second Generation H1-antihistamines.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-04-29; most recent amendment 2026-06-01.
Status change: Recruiting → Active, Not Recruiting 2026-06-01
Status change: Not Yet Recruiting → Recruiting 2024-12-23
Trial Details
NCT Number NCT06396026
Lead Sponsor Hangzhou Highlightll Pharmaceutical Co., Ltd
Conditions Chronic Spontaneous Urticaria
Enrollment 440 participants
Start Date 2024-03-27
Primary Completion 2025-10-23 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03